Drug Trial Radar · NCT04389632
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,006
Planned (sponsor's estimate)
Start
Jun 8, 2020
Primary completion
Jun 16, 2027
Study completion Mar 22, 2029
Sponsor
- Lead sponsor
- Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 15, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors. The study will have four parts. * Part A of the study will find out how much sigvotatug vedotin should be given to participants. * Part B will use the dose found in Part A to find out how safe sigvotatug vedotin is and if it works to treat solid tumors. * Part C of the study will find out how safe sigvotatug vedotin is in combination with these other drugs. * Part D will include people who have not received treatment. This part of the study will find out how safe sigvotatug vedotin is in combination with these other drugs and if these combinations work to treat solid tumors. * In Parts C and D, participants will receive sigvotatug vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin.
Conditions
- Carcinoma, Non-Small Cell Lung
- Squamous Cell Carcinoma of Head and Neck
- HER2 Negative Breast Neoplasms
- Esophageal Squamous Cell Carcinoma
- Esophageal Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Ovarian Neoplasms
- Cutaneous Squamous Cell Cancer
- Exocrine Pancreatic Adenocarcinoma
- Urinary Bladder Neoplasms
- Uterine Cervical Neoplasms
- Stomach Neoplasms
Interventions
sigvotatug vedotinDrug
Administered into the vein (IV; intravenously)
pembrolizumabDrug
200mg every 3 weeks or 400mg every 6 weeks, given by IV
cisplatinDrug
75 mg/m2 every 3 weeks, given by IV
carboplatinDrug
AUC 5 mg/mL per min every 3 weeks, given by IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Through 30-37 days following last dose of sigvotatug vedotin. For participants receiving pembrolizumab up to 90 days after last dose of pembrolizumab; up to 3 years
- Number of patients with laboratory abnormalitiesTime frame: Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years
- Number of participants with dose-limiting toxicities (DLTs)Time frame: Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years
Locations
158 sites in 7 countries. Site status is shown where the registry gives one.
Alaska Oncology and Hematology
Anchorage, Alaska · Recruiting
Highlands Oncology Group
Fayetteville, Arkansas · Recruiting
Highlands Oncology Group
Rogers, Arkansas · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
Providence Medical Foundation
Anaheim, California · Recruiting
Providence Medical Foundation
Fullerton, California · Recruiting
Providence St. Jude Medical Center Virginia K Crosson and Infusion Center
Fullerton, California · Recruiting
Cancer and Blood Research Center, LLC
Los Alamitos, California · Not yet recruiting
Cancer and Blood Specialty Clinic
Los Alamitos, California · Not yet recruiting
Ronald Reagan UCLA Medical Center
Los Angeles, California · Recruiting
The Regents of the University of California
Los Angeles, California · Recruiting
UCLA Department of Medicine-Hematology/Oncology
Los Angeles, California · Recruiting
UCLA Department of Medicine - Hematology & Oncology
Santa Monica, California · Recruiting
Cancer AND Blood Specialty Clinic
Torrance, California · Not yet recruiting
American Oncology Partners, PA. a Florida professional service corporation, d/b/a Vista Oncology
Fort Myers, Florida · Recruiting
Florida Cancer Specialists & Research Institute, LLC
Fort Myers, Florida · Recruiting
Memorial Cancer Institute
Hollywood, Florida · Recruiting
Memorial Healthcare System
Hollywood, Florida · Recruiting
Florida Cancer Specialists
Orlando, Florida · Recruiting
Memorial Cancer Institute at Memorial Hospital West
Pembroke Pines, Florida · Recruiting
Memorial Hospital West
Pembroke Pines, Florida · Recruiting
Ingalls Family Care Center
Calumet City, Illinois · Recruiting
UChicago Medicine - River East
Chicago, Illinois · Recruiting
The University Of Chicago
Chicago, Illinois · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
UChicago Medicine at Ingalls - Flossmoor
Flossmoor, Illinois · Recruiting
UChicago Medicine Ingalls Memorial
Harvey, Illinois · Recruiting
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
New Lenox, Illinois · Recruiting
The University of Chicago Medicine Center for Advanced Care Orland Park
Orland Park, Illinois · Recruiting
Southern Illinois University - Simmons Cancer Institute
Springfield, Illinois · Recruiting
Springfield Clinic Radiology - 800 Building
Springfield, Illinois · Recruiting
Springfield Clinic Urgent Care Plus
Springfield, Illinois · Recruiting
Springfield Clinic
Springfield, Illinois · Recruiting
Springfield Clinic Main Campus
Springfield, Illinois · Recruiting
Springfield Clinic Radiology - Main Campus
Springfield, Illinois · Recruiting
Springfield Memorial Hospital
Springfield, Illinois · Recruiting
UChicago Medicine at Ingalls - Tinley Park
Tinley Park, Illinois · Recruiting
UChicago Medicine - Northwest Indiana
Crown Point, Indiana · Recruiting
Fort Wayne Medical Oncology and Hematology, Inc
Fort Wayne, Indiana · Recruiting
Community Health Network, Inc
Indianapolis, Indiana · Recruiting
Showing 40 of 158 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.